| 2.1 -0.03 (-1.41%) | 05-16 13:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.65  |
1-year : | 2.99 |
| Resists | First : | 2.26 |
Second : | 2.55 |
| Pivot price | 2.18  |
|||
| Supports | First : | 1.79 |
Second : | 1.49 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 2.24 |
| MA(100) : | 4.74 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 23.8 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 17.3 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARTV ] has closed above bottom band by 37.6%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.21 - 2.23 | 2.23 - 2.24 |
| Low: | 1.79 - 1.81 | 1.81 - 1.82 |
| Close: | 2.11 - 2.13 | 2.13 - 2.15 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Tue, 13 May 2025
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data - GlobeNewswire
Sat, 10 May 2025
Artiva Biotherapeutics Reports Q1 2025 Progress - TipRanks
Thu, 08 May 2025
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewswire
Mon, 28 Apr 2025
Artiva Biotherapeutics to Present Longer-term Phase 1/2 - GlobeNewswire
Tue, 08 Apr 2025
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewswire
Mon, 31 Mar 2025
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 24 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 19.9 (%) |
| Held by Institutions | 91.4 (%) |
| Shares Short | 1,460 (K) |
| Shares Short P.Month | 1,080 (K) |
| EPS | -5.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -68.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|